MindMap Gallery Medicine - Bronchial Asthma
Internal medicine respiratory diseases, including causes, pathogenesis, clinical manifestations, physical signs, Check etc.
Edited at 2023-12-19 10:36:44Discover how Aeon can navigate the competitive online landscape with a strategic SWOT analysis. This comprehensive overview highlights Aeon’s strengths, such as its strong brand recognition, omnichannel capabilities, and customer loyalty programs, alongside its weaknesses, including digital maturity gaps and cost structure challenges. Opportunities for growth include enhancing e-commerce competitiveness and leveraging data-driven strategies, while threats from online-first players and market dynamics require attention. Explore how Aeon can strengthen its market position through innovation and customer-centric approaches in the ever-evolving retail environment.
Discover how Aeon effectively tailors its offerings to meet the diverse needs of family-oriented consumers through a comprehensive Segmentation, Targeting, and Positioning (STP) analysis. Our approach begins with demographic segmentation, examining family life stages, household sizes, income levels, and parent age bands to identify distinct consumer groups. Geographic segmentation highlights store catchment types and community characteristics, while psychographic segmentation delves into family values and lifestyle orientations. Behavioral segmentation focuses on shopping missions, price sensitivity, and channel preferences. Finally, needs-based segmentation reveals core family needs related to value and budget considerations. Join us as we explore these insights to enhance family shopping experiences at Aeon.
Discover the dynamics of sneaker transactions with our Kream Sneaker Consumption Scene Analysis Template. This comprehensive framework aims to visualize the purchasing and consumption journeys of sneakers, identifying key demand drivers and obstacles. It covers user behavior within Kream and external influences, targeting various sneaker categories over specific timeframes and regions. The analysis defines user segments, including collectors, resellers, sneakerheads, casual trend followers, and gift purchasers, each with unique values and KPIs. It outlines the consumption journey from awareness to resale, highlighting critical touchpoints such as search, purchase, inspection, and sharing experiences. Key performance indicators are established to measure engagement and satisfaction throughout the process. Join us in exploring the intricate world of sneaker trading!
Discover how Aeon can navigate the competitive online landscape with a strategic SWOT analysis. This comprehensive overview highlights Aeon’s strengths, such as its strong brand recognition, omnichannel capabilities, and customer loyalty programs, alongside its weaknesses, including digital maturity gaps and cost structure challenges. Opportunities for growth include enhancing e-commerce competitiveness and leveraging data-driven strategies, while threats from online-first players and market dynamics require attention. Explore how Aeon can strengthen its market position through innovation and customer-centric approaches in the ever-evolving retail environment.
Discover how Aeon effectively tailors its offerings to meet the diverse needs of family-oriented consumers through a comprehensive Segmentation, Targeting, and Positioning (STP) analysis. Our approach begins with demographic segmentation, examining family life stages, household sizes, income levels, and parent age bands to identify distinct consumer groups. Geographic segmentation highlights store catchment types and community characteristics, while psychographic segmentation delves into family values and lifestyle orientations. Behavioral segmentation focuses on shopping missions, price sensitivity, and channel preferences. Finally, needs-based segmentation reveals core family needs related to value and budget considerations. Join us as we explore these insights to enhance family shopping experiences at Aeon.
Discover the dynamics of sneaker transactions with our Kream Sneaker Consumption Scene Analysis Template. This comprehensive framework aims to visualize the purchasing and consumption journeys of sneakers, identifying key demand drivers and obstacles. It covers user behavior within Kream and external influences, targeting various sneaker categories over specific timeframes and regions. The analysis defines user segments, including collectors, resellers, sneakerheads, casual trend followers, and gift purchasers, each with unique values and KPIs. It outlines the consumption journey from awareness to resale, highlighting critical touchpoints such as search, purchase, inspection, and sharing experiences. Key performance indicators are established to measure engagement and satisfaction throughout the process. Join us in exploring the intricate world of sneaker trading!
2. Bronchial asthma
Cause
genetic factors
① This disease has a family aggregation phenomenon. The closer the genetic relationship, the higher the prevalence rate.
② Multiple asthma susceptibility gene loci have been identified, such as 5q12, 22, 23, 17q12~17, 9q24, etc.
envirnmental factor
①Allergen factors, such as indoor allergens, outdoor allergens, occupational allergens, food, drugs (aspirin, antibiotics)
②Non-allergenic factors, such as air pollution, smoking, exercise, obesity, etc.
Pathogenesis
Immune-inflammatory mechanisms
① The chronic inflammatory response of the airway is the joint participation of a variety of inflammatory cells (T lymphocytes, B lymphocytes, mast cells, basophils, eosinophils, etc.), inflammatory mediators and cytokines
②The main inflammatory cells are: eosinophils, and the participating antibodies are: lgE
Airway hyperresponsiveness (AHR)
①Chronic inflammation of the airways is one of the important mechanisms leading to AHR
②AHR is a basic characteristic of asthma and can be quantified and evaluated through bronchial provocation testing
airway remodeling
Manifested as airway epithelial cell mucus metaplasia, smooth muscle hypertrophy/proliferation, subepithelial collagen deposition and fibrosis, vascular proliferation, etc.
clinical manifestations
main performance
① Paroxysmal expiratory dyspnea accompanied by wheezing
②Can be relieved after treatment with antiasthmatic drugs or by itself
③Important clinical features of asthma during nighttime and early morning attacks
special performance
Especially in teenagers, asthma symptoms appear during exercise, which is called exercise-induced asthma.
severe asthma
① Clinically, there are atypical asthma without wheezing symptoms. Patients may present with paroxysmal cough, chest tightness or other symptoms.
② Atypical asthma with chest tightness as the only symptom is called chest tightness variant asthma
physical signs
Typical signs
① During the attack, widespread wheezing can be heard in both lungs, and the expiration phase is prolonged.
② In a very severe asthma attack, the wheezing sound weakens or even disappears completely, showing a "silent chest", which is a sign of a critical condition.
non-ictal signs
There may be no abnormal findings, so the absence of wheezing cannot rule out asthma.
examine
1. Sputum smear
Cough variant asthma can be diagnosed by showing more eosinophils in sputum smear
2. Pulmonary function test
Ventilation function test
① Obstructive ventilatory dysfunction occurs during an asthma attack (Teacher Zhaozhao reminds: It is very similar to COPD, but COPD is irreversible, while asthma is reversible)
②Ventilation indicators: FEV1↓; FEV1/FVC↓; vital capacity (VC)↓; maximum expiratory flow (PEF)↓; maximum mid-expiratory flow rate (MMFR)↓; maximum expiratory volume (MEF)↓
Bronchial Provocation Test (BPT)
① Inhalation stimulants are acetylcholine, histamine, etc. If the FEV1 decreases by ≥20%, the result is positive, indicating the presence of airway hyperresponsiveness.
②This test is contraindicated during acute attack
Bronchodilation Test (BDT)
①To measure reversible changes in the airway
② Inhaled bronchodilators include albuterol and terbutaline. Repeat the lung function measurement 20 minutes after inhaling the bronchodilator. If FEV1 increases by ≥12% compared with before taking the medication, and its absolute value increases by ≥200ml, the result is positive, indicating reversibility. sexual airway obstruction
Determination of PEF and its mutation rate
①PEF decreases during asthma attack
② Diurnal PEF variation rate ≥20%, indicating the existence of reversible airway changes
3. Arterial blood gas analysis
Early days
Due to hyperventilation, PaCO2 decreases and pH increases, manifesting as: respiratory alkalosis
later stage
Respiratory acidosis (CO2 retention) occurs when hypoxia worsens. Metabolic acidosis (increased lactic acid due to hypoxia) indicates aggravation of the patient's condition.
4. Chest X-ray and CT examination
X-ray
During an asthma attack, the chest X-ray shows that the transparency of both lungs increases, showing a state of hyperventilation. There are usually no obvious abnormalities during the remission period.
Chest CT
Chest CT shows bronchial wall thickening and mucus obstruction in some patients
5. Specific allergens
(1) Serum total IgE measurement has little value in the diagnosis of asthma.
(2) The degree of increased IgE can be used as a basis for anti-IgE antibody treatment and dosage adjustment in severe asthma.
condition assessment
1. Assessment of asthma severity during acute exacerbations
symptom
Mild
Shortness of breath and possible anxiety when walking or going upstairs
Moderate
I feel short of breath when I move a little bit, my speech is often interrupted, and I feel anxious from time to time.
Severe
I feel short of breath when resting, sit upright and breathe, can only express single words, often feel anxious and irritable, and sweat profusely.
critical
The patient cannot speak, is drowsy or confused
physical signs
Mild
The respiratory rate increased slightly and scattered wheezing sounds were heard.
Moderate
① The respiratory rate increases, there may be three concave signs, and a loud and diffuse wheezing sound may be heard
②The heart rate increases and strange pulse may occur
Severe
① Respiratory rate >30 times/min, often with three concave signs, and loud, diffuse wheezing.
② Increased heart rate often >120 beats/min, abnormal pulse
critical
①Contradictory movements of chest and abdomen
② The wheezing sound weakens or even disappears, and the pulse rate becomes slow or irregular
examine
Mild
Pulmonary ventilation function and blood gas tests were normal
Moderate
After using bronchodilators, PEF accounts for 60% to 80% of the predicted value, and Sa02 91% to 95%
Severe
① After using bronchodilators, PEF accounts for <60% of the predicted value or absolute value <100L/min or action time <2 hours ②Pa02<60mmHg, PaCO2>45mmHg, Sa02≤90%, pH can be reduced
critical
Severe hypoxemia and hypercapnia, decreased pH
2. Chronic duration
Current Clinical Control Assessment
① Evaluation criteria: Daytime asthma symptoms > 2 times/week; Awakening due to asthma at night; Use of relievers > 2 times/week; Limitation of activities caused by asthma
② If there are no symptoms above, it is under good control; if there are 1 to 2 items, it is under partial control; if there are 3 to 4 items, it is under control.
Future risk assessment
Factors associated with increased risk of future adverse events include: poor clinical control; frequent exacerbations in the past year; previous hospitalization for severe asthma; low FEV1; tobacco exposure; high-dose medication
3.Clinical remission period
It means that the patient has no symptoms such as wheezing, shortness of breath, chest tightness, cough, etc., and has maintained them for more than 1 year.
treat
1. Identify and reduce exposure to risk factors
Some patients can find allergens or other non-specific irritants that cause asthma attacks. Isolating patients and avoiding exposure to these risk factors for a long time is an effective way to prevent and treat asthma.
2. Drug treatment - drug classification
Relief drugs
Mainly to reduce symptoms - used during acute attacks
①Short-acting β2-receptor agonist (SABA)
②Short-acting inhaled anticholinergic drugs (SAMA)
③Short-acting theophylline
④ Systemic glucocorticoids
Controller drugs
Mainly to slow down the onset - used in the chronic period
①Inhaled glucocorticoids
②Leukotriene regulator (montelukast)
③Long-acting β2-receptor agonist (LABA)
④Slow-release theophylline
⑤Sodium cromoglycate
⑥Anti-lgE antibody
⑦Anti-IL-5 antibody
⑧Combined drugs (such as ICS/LABA)
3. Drug therapy - specific applications and characteristics of drugs
(1) Glucocorticoids
mechanism
①Referred to as hormones, they are currently the most effective drugs for controlling asthma.
② Hormones effectively inhibit airway inflammation by acting on many aspects of the process of inflammation, such as inhibiting the aggregation of eosinophils and other inflammatory cells in the airways, inhibiting the production and release of inflammatory mediators, and enhancing the responsiveness of β2 receptors in smooth muscle cells. Tract inflammation.
Dosage form
Inhalation type
①The current drug of choice for long-term treatment of asthma
② It usually takes more than 1 to 2 weeks of regular inhalation to take effect.
Oral type
①For patients who are ineffective with inhaled corticosteroids or require short-term intensive treatment
②Preferred drug: prednisone or prednisolone
Venous type
① In severe or severe asthma attacks, intravenous steroid treatment should be given as soon as possible
②Preferred drug: hydrocortisone or methylprednisolone
(2) β2 receptor agonist
mechanism
Mainly by stimulating β2 adrenal receptors in the airways, activating adenylate activating enzyme, reducing degranulation of mast cell nuclei and basophils and the release of mediators, thereby relaxing the airways and relieving asthma symptoms.
preparation
①Short-acting β2-receptor agonist (SABA) → albuterol, terbutaline, etc. ②Long-acting β2-receptor agonist (LABA) → salmeterol, etc.
(3)Leukotriene regulator
mechanism
① It exerts anti-inflammatory effects by regulating the biological activity of leukotrienes and can relax bronchial smooth muscle at the same time.
② Currently, apart from inhaled corticosteroids, it is the only asthma control drug that can be used alone
Indications
①Can be used as an alternative treatment drug for ICS in mild asthma and as a combined treatment drug for moderate and severe asthma
②Especially suitable for patients with aspirin asthma, exercise-induced asthma and asthma with allergic rhinitis
preparation
Montelukast, Zafirlukast, etc.
Adverse reactions
Gastrointestinal symptoms, a few have rash, etc.
(4) Theophylline
mechanism
By inhibiting diphosphatase, it increases the concentration of cyclic AMP in smooth muscle cells, antagonizes adenosine receptors, enhances the strength of respiratory muscles and enhances the clearance function of airway cilia, thereby relaxing the bronchial and airway anti-inflammatory effects. One of the most effective drugs for treating asthma
Indications
① Orally used for mild to moderate asthma
② Intravenous administration is mainly used for severe and critical asthma
Adverse reactions
Nausea, vomiting, arrhythmia, etc.
(5) Anticholinergic drugs
mechanism
① By blocking the vagus nerve pathway and reducing vagus nerve tone, it relaxes the bronchi and reduces mucus.
② Its bronchodilator effect is weaker than that of β2 receptor agonists
Commonly used medicines
①Short-acting preparations→ipratropium bromide, etc.
②Long-acting preparation → tiotropium bromide, etc.
(6) Anti-lgE antibody and anti-IL-5 treatment
anti-lgE antibody
It is mainly used for patients with severe asthma whose symptoms are not controlled and whose serum IgE level is increased after taking inhaled glucocorticoids and long-acting β2-receptor agonists.
Anti-IL-5 treatment
①IL-5 is an important cytokine that promotes the increase, accumulation and activation of eosinophils in the lungs
② The treatment of asthma with anti-IL-5 monoclonal antibodies can reduce eosinophil infiltration in patients, reduce acute exacerbations of asthma and improve patients’ quality of life. It has a good therapeutic effect on asthma patients with hypereosinophilia.
(7)Sodium tryptophan
Can be used to prevent asthma attacks
4. Drugs of choice in different periods
(1) Acute attack period
① Mild: intermittent short-acting β2 receptor agonist
② Moderate: Inhaled short-acting β2 receptor agonists, inhaled hormones, oral hormones are not effective
③Severe: Continuous inhalation of short-acting β2 receptor agonists and intravenous application of hormones
④If PaC02≥45mmHg, consciousness changes, invasive mechanical ventilation is required
(2) Chronic duration
For most patients with untreated persistent asthma, initial treatment should begin with a Level 2 regimen, and if initial assessment indicates severe uncontrolled asthma, treatment should begin with a Level 3 regimen.